1. Home
  2. LGN vs VKTX Comparison

LGN vs VKTX Comparison

Compare LGN & VKTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Legence Corp.

LGN

Legence Corp.

HOLD

Current Price

$55.86

Market Cap

4.1B

Sector

N/A

ML Signal

HOLD

VKTX

Viking Therapeutics Inc.

HOLD

Current Price

$28.95

Market Cap

4.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
LGN
VKTX
Founded
1963
2012
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1B
4.0B
IPO Year
2025
2014

Fundamental Metrics

Financial Performance
Metric
LGN
VKTX
Price
$55.86
$28.95
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
17
7
Target Price
$59.50
$95.86
AVG Volume (30 Days)
778.9K
1.8M
Earning Date
05-15-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$2,550,491,000.00
N/A
Revenue This Year
$53.66
N/A
Revenue Next Year
$11.99
N/A
P/E Ratio
N/A
N/A
Revenue Growth
21.53
N/A
52 Week Low
$29.00
$24.52
52 Week High
$107.24
$43.15

Technical Indicators

Market Signals
Indicator
LGN
VKTX
Relative Strength Index (RSI) 45.68 30.44
Support Level $48.60 $26.47
Resistance Level $58.28 $35.36
Average True Range (ATR) 2.53 1.35
MACD 0.58 -0.46
Stochastic Oscillator 60.94 6.26

Price Performance

Historical Comparison
LGN
VKTX

About LGN Legence Corp.

Legence Corp is a provider of engineering, installation, and maintenance services for critical systems in buildings. It focuses on sectors that have technically demanding buildings, including technology, life sciences, healthcare, and education. Legence specializes in designing, fabricating, and installing complex heating, ventilation, and air conditioning (HVAC), process piping, and other mechanical, electrical, and plumbing (MEP) systems for new facilities and upgrading HVAC, lighting, and building controls in existing facilities to enhance building performance, reliability, and efficiency. The services are mainly provided on a fixed price basis. The company has two reportable segments: Installation and Maintenance, which generates the maximum revenue, and Engineering and Consulting.

About VKTX Viking Therapeutics Inc.

Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.

Share on Social Networks: